Peter O'Donnell is a freelance journalist who specializes in European health affairs and is based in Brussels, Belgium.

Articles

A draft report from parliament's cancer committee highlights the benefits that precision and personalized medicine offer.

Faint Ripples of Support Detected in Europe for High-Tech Drug Development

A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients.

Drug Prices Targeted in Biden Competition Initiative

Micki Hultquist, Vice President, Global Franchise Head at AstraZeneca, discusses the journey from a missed endpoint in TULIP-1 to a clinical success in TULIP-2

Digging into the TULIP Trials and AstraZeneca’s Blossoming Ambitions in Lupus

FDA acting commissioner Janet Woodcock has bowed to pressure and called on the HHS’s Office of the Inspector General to examine the review process for Biogen’s Alzheimer’s disease treatment, Aduhelm.

Woodcock Seeks Outside Investigation to Restore FDA Credibility

The Center for Biologics Evaluation and Research’s top priority is to approve biologics license applications (BLAs) to address vaccine hesitancy, according to CBER director Peter Marks.

Full Approval of COVID Vaccines Key to Addressing Hesitancy

The latest draft supports the creation of the Biden administration’s proposed Advanced Research Projects Agency for Health to accelerate research on cures for cancer, diabetes, Alzheimer’s and more. 

New “Cures” Bill Aims to Advance R&D, Drug Development

Not just COVID is changing the landscape of pharmaceutical policy in Europe.

Convergent Drivers of European Medicines Policy

CDER launches an initiative to gain more efficient and transparent operations of its advisory panels. Jill Wechsler reports.

FDA Advisory Committees Under Scrutiny

Thad Wolfram, President, Matrix Clinical Trials at Matrix Medical Network, speaks about his experience utilizing decentralization methodologies to increase clinical trial diversity inclusion by going deep into diverse communities.

How the Pandemic Facilitated Clinical Trial Diversity Inclusion

Allegedly more than 4,000 clinical trials of medicines are missing results on the European trial registry, in violation of transparency rules. 

Blogs